---
title: UCL to use Quattrii to advance inhaled antibody and RNA medicines
description: UCL will leverage CHI's Quattrii dry powder inhaler to develop innovative inhaled antibody and RNA medicines for severe respiratory diseases.
image: https://chi.uk/hubfs/UCL%20announcement.png
---
[Skip to content](https://chi.uk/chi-blog/ucl-to-use-quattrii-to-advance-inhaled-antibody-and-rna-medicines#main-content)
Close
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
SEARCH
Contact us
[](https://chi.uk/home)
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
Contact us
Quick results for "{search\_term}"
[Neil Cooper](https://chi.uk/chi-blog/author/neil-cooper)Nov 4, 2026, 10:00:03 AM2 min read
# UCL to use Quattrii to advance inhaled antibody and RNA medicines
[Previous](https://chi.uk/chi-blog/stop-letting-the-inhaler-limit-the-medicine)
#### Cambridge Healthcare Innovations’ dry powder inhaler platform will support research into high-payload formulations for severe asthma, COPD, cystic fibrosis, and lung cancer.
University College London ([UCL](https://www.ucl.ac.uk/)) plans to use CHI's Quattrii™ dry powder inhaler platform to evaluate novel inhaled biologic formulations, including antibody and RNA therapeutics.
The research, led by Professor of Pharmaceutics [Dr Jenny Lam](https://profiles.ucl.ac.uk/88272-jenny-lam), aims to address unmet needs in respiratory diseases including severe asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and lung cancer. Her laboratory is developing dry powder formulations with the aim of improving stability, extending shelf life, and making treatment more convenient for patients.
For these medicines, formulation development and device selection are closely connected. Biologic therapeutics can require relatively high doses, creating a practical challenge: delivering enough powder with reliable aerosol performance. A promising formulation may be difficult to progress if the inhaler cannot accommodate the required payload or disperse it effectively.
Quattrii was designed to address this challenge. Its high-payload blister format accommodates substantial powder fill masses, while cyclonic airflow supports powder dispersion. Individual foil–foil blisters protect the formulation from moisture until use. Devices are available in medical-grade plastic for laboratory evaluation and clinical trials, allowing researchers to consider the delivery platform’s suitability beyond initial laboratory testing.
Professor Jenny Lam, UCL, said: “Our laboratory is developing inhaled antibody and RNA therapeutics for respiratory diseases where there remains a substantial need for better treatments. We want to produce stable dry powders that have a longer shelf life and are convenient for patients, but we also need a device that can deliver the powder effectively at the doses these medicines may require.
“Quattrii’s combination of high powder capacity and its approach to aerosol delivery makes it well suited to the work we want to undertake. Evaluating our formulations in the platform will help us understand how we can bring formulation stability, dose requirements, and aerosol performance together.”
The planned work will explore how UCL’s formulations perform in Quattrii, helping the researchers assess delivery at the powder payloads relevant to their development programmes. Considering these requirements early can help identify and resolve device constraints before they become barriers to further development.
David Harris, CEO of CHI, said: “Researchers are developing biologic medicines with enormous potential, but their work can be held back by a very practical problem: finding an inhaler that can handle the amount of powder they need to deliver. That is one of the problems we designed Quattrii to solve.
“We are delighted that Professor Lam’s team wants to use the platform. Our aim is to give formulation scientists the freedom to pursue promising medicines, with a device that supports their dose and delivery requirements. This work is an opportunity to help unlock that potential for inhaled antibodies and RNA therapeutics.”
**Quattrii is available for pre-evaluation and clinical trials, as well as select academic programmes. Contact CHI to discuss your formulation, required dose and inhalation conditions in confidence and agree an evaluation protocol: [quattrii@chi.uk](mailto:quattrii@chi.uk)**
#### [Neil Cooper](https://chi.uk/chi-blog/author/neil-cooper)
Neil is responsible for developing, executing and leading the company's commercial and operations strategy. As well as considerable leadership experience within technology-licensing and start-ups, he is also an inventor on nine patents.
[mailto:neil.cooper@chi.uk](mailto:neil.cooper@chi.uk)
## RELATED ARTICLES
Button Title
All rights reserved, Cambridge Healthcare Innovations Ltd 2024
- [Privacy policy](https://chi.uk/policies)
- Registered in England & Wales (GB11540827)
- [329 Cambridge Science Park, Cambridge CB4 0WG, UK](https://chi.uk/about-us#Contact)
```json
{
"@context" : "https://schema.org",
"@type" : "Organization",
"knowsLanguage" : "en",
"logo" : {
"@type" : "ImageObject",
"url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg"
},
"name" : "",
"url" : "https://chi.uk/chi-blog/ucl-to-use-quattrii-to-advance-inhaled-antibody-and-rna-medicines"
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"abstract" : "UCL will leverage CHI's Quattrii dry powder inhaler to develop innovative inhaled antibody and RNA medicines for severe respiratory diseases.",
"author" : {
"@type" : "Person",
"name" : "Neil Cooper"
},
"dateModified" : "November 4, 2026 10 AM",
"datePublished" : "November 4, 2026 10 AM",
"headline" : "UCL to use Quattrii to advance inhaled antibody and RNA medicines",
"image" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/UCL%20announcement.png",
"inLanguage" : "en",
"keywords" : "[Announcement, biologics, quattrii]",
"mainEntityOfPage" : {
"@type" : "WebPage"
},
"name" : "UCL to use Quattrii to advance inhaled antibody and RNA medicines",
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg"
},
"name" : ""
},
"text" : "Cambridge Healthcare Innovations’ dry powder inhaler platform will support research into high-payload formulations for severe asthma, COPD, cystic fibrosis, and lung cancer. University College London (UCL) plans to use CHI's Quattrii™ dry powder inhaler platform to evaluate novel inhaled biologic formulations, including antibody and RNA therapeutics. The research, led by Professor of Pharmaceutics Dr Jenny Lam, aims to address unmet needs in respiratory diseases including severe asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and lung cancer. Her laboratory is developing dry powder formulations with the aim of improving stability, extending shelf life, and making treatment more convenient for patients. For these medicines, formulation development and device selection are closely connected. Biologic therapeutics can require relatively high doses, creating a practical challenge: delivering enough powder with reliable aerosol performance. A promising formulation may be difficult to progress if the inhaler cannot accommodate the required payload or disperse it effectively. Quattrii was designed to address this challenge. Its high-payload blister format accommodates substantial powder fill masses, while cyclonic airflow supports powder dispersion. Individual foil–foil blisters protect the formulation from moisture until use. Devices are available in medical-grade plastic for laboratory evaluation and clinical trials, allowing researchers to consider the delivery platform’s suitability beyond initial laboratory testing. Professor Jenny Lam, UCL, said: “Our laboratory is developing inhaled antibody and RNA therapeutics for respiratory diseases where there remains a substantial need for better treatments. We want to produce stable dry powders that have a longer shelf life and are convenient for patients, but we also need a device that can deliver the powder effectively at the doses these medicines may require. “Quattrii’s combination of high powder capacity and its approach to aerosol delivery makes it well suited to the work we want to undertake. Evaluating our formulations in the platform will help us understand how we can bring formulation stability, dose requirements, and aerosol performance together.” The planned work will explore how UCL’s formulations perform in Quattrii, helping the researchers assess delivery at the powder payloads relevant to their development programmes. Considering these requirements early can help identify and resolve device constraints before they become barriers to further development. David Harris, CEO of CHI, said: “Researchers are developing biologic medicines with enormous potential, but their work can be held back by a very practical problem: finding an inhaler that can handle the amount of powder they need to deliver. That is one of the problems we designed Quattrii to solve. “We are delighted that Professor Lam’s team wants to use the platform. Our aim is to give formulation scientists the freedom to pursue promising medicines, with a device that supports their dose and delivery requirements. This work is an opportunity to help unlock that potential for inhaled antibodies and RNA therapeutics.” Quattrii is available for pre-evaluation and clinical trials, as well as select academic programmes. Contact CHI to discuss your formulation, required dose and inhalation conditions in confidence and agree an evaluation protocol: quattrii@chi.uk",
"url" : "https://chi.uk/chi-blog/ucl-to-use-quattrii-to-advance-inhaled-antibody-and-rna-medicines",
"wordCount" : "601"
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Neil Cooper",
"url" : "https://chi.uk/chi-blog/author/neil-cooper"
},
"dateModified" : "2026-11-04T10:00:03.395Z",
"datePublished" : "2026-11-04T10:00:03.000Z",
"headline" : "UCL to use Quattrii to advance inhaled antibody and RNA medicines",
"image" : [ "https://chi.uk/hubfs/UCL%20announcement.png" ],
"mainEntityOfPage" : {
"@id" : "https://chi.uk/chi-blog/ucl-to-use-quattrii-to-advance-inhaled-antibody-and-rna-medicines",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://chi.uk/hubfs/CHI.svg"
},
"name" : "Cambridge Healthcare Innovations Ltd."
}
}
```